Humana may also make an acquisition deal and UnitedHealth buys a unit of DaVita; a look at the FDA's expedited review programs; how a billing code discrepancy may have cost taxpayers up to $102 million in Medicare payments to hospitals.
After the CVS—Aetna deal was announced, rumors began swirling that Humana may be next in line for a big deal. Earlier this year, the proposal for Aetna to purchase Humana was blocked by federal judges, and now Humana is making moves that seem to indicate a sale, reported Fierce Healthcare. While the most likely deal would be with Cigna, Humana could also be acquired by Walmart or Walgreens, which would follow in the footsteps of Aetna’s merger across business lines. Meanwhile, UnitedHealth announced it will buy DaVita's primary care unit for $4.9 billion. Reuters reported that DaVita's physician network serves 1.7 million patients every year, but had been a draf on the company's financial performance recently.
A research letter in JAMA analyzed the FDA’s 4 expedited programs to speed up development and review drugs for certain diseases and the outcomes of these drugs. Overall, 60% of new drug approvals from January 2012 to December 2016 were in at least 1 expedited program. The authors compared development times for drugs with priority review or accelerated approval and compared them with drugs not in an expedited program and found that median time from application to approval was almost a full year (0.9 years) shorter for drugs in an expedited program.
For 7 years a Medicare billing code issue may have cost taxpayers up to $102 million in wasteful payments to hospitals. CNBC reported that the issue stemmed from a discrepancy in diagnosis codes—a form of severe protein malnutrition that is rare in the United States had the same code number as less severe forms of malnutritions on one list that is a tool for billing. On another list of coding classification, the rare form had a different code. The number of claims using the code rose from 11,000 to 45,000 a year from 2006 to 2009. The number of claims started to drop after 2009 when the American Hospital Association issued guidance and the discrepancy was fixed in 2015 with the International Classification of Diseases, 10th Revision.
Telephone Follow-Up on Medicare Patient Surveys Remains Critical
January 16th 2025Including a telephone component in Medicare Consumer Assessment of Healthcare Providers and Systems survey administration continues to be valuable because telephone responses comprise a substantial portion of responses for several underserved groups.
Read More
Quantifying the Altruism Value for a Rare Pediatric Disease: Duchenne Muscular Dystrophy
January 14th 2025Altruism values for treatments of rare, severe pediatric diseases have not been estimated. This study found the altruism value for a hypothetical new Duchenne muscular dystrophy treatment to be $80 per year.
Read More
Health Equity & Access Weekly Roundup: January 11, 2025
January 11th 2025ACA enrollment rate hits a milestone, though IRA subsidies may not extend beyond 2025; network adequacy standards fail to translate into efficient access to mental health care for Medicaid enrollees; research examines racial disparities in postpartum hypertension and vaccine uptake.
Read More